differ
note
rotaviru
vaccin
effici
high
low
incom
countri
correl
lack
univers
access
clean
water
higher
standard
hygien
overcom
obstacl
requir
great
invest
also
time
therefor
effect
vaccin
develop
meet
need
would
benefit
increas
current
knowledg
mucos
immun
respons
rotaviru
infect
modul
circadian
rhythm
could
point
action
pathway
improv
vaccin
efficaci
especi
case
individu
affect
environment
enteropathi
also
better
understand
valid
rotaviru
entri
factor
well
systemat
monitor
domin
strain
could
assist
tailor
vaccin
individu
need
anoth
aspect
could
improv
vaccin
effici
target
cell
new
ligand
could
potenti
sought
final
altern
mucos
adjuv
vaccin
express
storag
deliveri
system
could
posit
impact
outcom
rotaviru
vaccin
articl
histori
vaccin
gener
accept
one
success
prophylact
intervent
histori
develop
requir
sustain
effort
research
improv
efficaci
mitig
risk
oral
vaccin
great
benefit
administ
easili
critic
especi
larg
mass
vaccin
campaign
develop
nation
well
establish
environment
factor
climat
poverti
nutrit
diseas
take
great
toll
effici
vaccin
circumst
big
impact
underprivileg
popul
especi
develop
nation
argu
mani
healthcar
solut
origin
develop
address
need
higher
incom
nation
inadequ
realiti
face
develop
countri
infer
instanc
studi
outcom
oral
vaccin
contrast
set
regard
environment
enteropathi
ee
believ
play
signific
critic
role
ee
subclin
condit
frequent
encount
lower
incom
nation
attribut
combin
factor
includ
repeat
exposur
oralfaec
contamin
inadequ
nutrit
poor
overal
sanit
ultim
ee
may
lead
small
intestin
bacteri
overgrowth
gut
microbiom
imbal
ee
also
correl
stunt
affect
individu
varieti
symptom
decreas
intestin
barrier
function
reduc
nutrient
absorpt
capac
increas
gut
permeabl
facilit
cross
pathogen
subsequ
activ
immun
system
like
chronic
gut
inflamm
contribut
growth
abnorm
stunt
also
major
histolog
modif
small
intestin
includ
shorten
villi
chang
may
revers
time
improv
nutrit
sanitari
condit
lead
lower
nutrient
absorpt
surfac
reduc
benefit
intervent
includ
supplement
vaccin
critic
time
ee
onset
transit
breastfeed
complementari
feed
risk
oralfaec
contamin
greatli
augment
neg
impact
ee
mitig
vari
degre
success
improv
hygien
nutrit
supplement
zinc
micronutri
lipid
alanylglutamin
vitamin
proprebiot
also
antibiot
instanc
urban
bangladeshi
slum
ee
strong
impact
oral
polio
rotaviru
immun
perform
parenter
administr
gut
microbiom
administr
proprebiot
influenc
vaccin
efficaci
also
receiv
consider
attent
vari
level
success
huda
colleagu
analys
microbiom
composit
stool
sampl
bangladeshi
children
immun
oral
polio
viru
opv
bacil
bcg
tetanu
toxoid
tt
hepat
b
viru
note
actinobacteria
especi
bifidobacterium
longum
ssp
infanti
predomin
posit
correl
opv
bcg
tt
polyclon
cell
prolifer
author
also
found
neg
correl
presenc
enterobacterial
pseudomonadal
clostridial
vaccin
respons
anoth
clinic
studi
india
involv
infant
analys
influenc
probiot
also
zinc
immunogen
oral
rotarix
rotaviru
vaccin
normal
cours
two
dose
administ
week
age
without
daili
zinc
mg
probiot
lactobacillu
rhamnosu
gg
placebo
gain
vaccin
immunogen
could
associ
probiot
p
zinc
alon
modest
gain
suggest
studi
similar
probiot
strain
also
parker
colleagu
use
clinic
trial
set
evalu
incid
bacteri
viral
eukaryot
pathogen
well
microbiom
composit
infant
respect
author
could
find
strong
associ
vaccin
immunogen
microbiom
note
also
colon
l
rhamnosu
gg
passiv
rather
success
pathogen
burden
infant
fail
respond
vaccin
compar
overal
singl
solut
entir
overcom
ee
holist
approach
gener
advis
expert
postul
reduc
level
ee
may
prove
critic
increas
oral
vaccin
efficaci
estim
worldwid
approxim
children
year
age
die
annual
consequ
diarrhea
rotaviru
gastroenter
rge
lead
caus
diarrheal
death
total
estim
age
among
year
old
rotavirus
first
identifi
electron
microscopi
intestin
biopsi
children
diagnos
acut
gastroenter
virus
consist
nonenvelop
icosahedr
particl
compris
segment
dsrna
encod
structur
nonstructur
protein
cleavag
lead
involv
cell
penetr
head
spike
requir
attach
infect
intestin
cell
infect
naturallyoccur
rotaviru
strain
confer
immun
prevent
strong
diarrhea
upon
reinfect
post
reinfect
serotyp
respons
normal
broader
antibodi
respons
limit
outer
capsid
protein
includ
also
neutral
iga
specif
prevent
adsorpt
uncoat
penetr
iga
prevent
intracellular
viral
replic
transcytosi
across
enterocyt
outer
capsid
protein
use
p
proteas
g
glycoprotein
serotyp
genotyp
epidemiolog
studi
indic
rotaviru
divers
chang
year
within
countri
point
mutat
genet
drift
lead
antigen
chang
reassort
within
anim
strain
infect
speci
well
genet
rearrang
review
preval
rotaviru
strain
report
nation
note
strain
divers
associ
accumul
point
mutat
drive
antigen
drift
genom
reassort
zoonot
transmiss
five
genotyp
account
strain
declin
onward
reappear
concurr
emerg
strain
increas
africa
decreas
interest
note
africa
p
strain
compris
genotyp
europ
north
america
account
less
rotaviru
infect
take
place
via
apic
tip
villi
within
small
intestin
replic
occur
primarili
differenti
epitheli
cell
ultim
lead
cell
death
turn
lead
limit
food
digest
releas
fluid
caus
diarrhea
interact
glycan
critic
earli
stage
rotaviru
infect
histoblood
group
antigen
hbga
express
surfac
red
blood
epitheli
cell
serv
nonsialyl
glycan
bind
partner
rotaviru
entri
via
protein
within
narrow
cleft
wide
determin
bind
cellsurfac
glycan
hbga
express
genet
determin
addit
monosaccharid
precursor
disaccharid
activ
abh
gene
secretor
gene
lewi
gene
loss
function
mutat
lead
secretorand
lewisneg
phenotyp
individu
determin
rotaviru
specif
eg
strain
p
narrow
cleft
allow
bind
atyp
hbga
atyp
bind
also
seen
p
p
strain
furthermor
p
strain
associ
high
rate
infect
newborn
india
strain
recogn
type
ii
precursor
glycan
lactonbios
nacetyllactosamin
respect
becom
less
preval
age
also
infect
common
p
genotyp
correl
hbga
secretor
statu
instanc
loss
function
lead
virtual
infect
p
strain
countri
like
vietnam
usa
tunisia
among
children
infect
p
present
secretor
nonsecretor
posit
lewi
antigen
also
pakistan
studi
compris
infant
seroneg
immun
three
cours
vaccin
strain
indic
respond
nonsecretor
wherea
secretor
type
type
b
ab
addit
p
infect
total
seen
predominantli
lewisneg
children
frequent
phenotyp
african
popul
lewisneg
individu
resist
p
infect
total
children
studi
note
children
nicaragua
burkina
faso
infect
p
strain
secretor
lewi
posit
rotaviru
also
enter
bodi
via
cell
locat
within
follicleassoci
epithelia
fae
cell
possess
structur
function
trait
allow
transport
antigen
adjac
mucosalassoci
lymphoid
tissu
small
intestin
cell
concentr
around
aggreg
lymphoid
follicl
call
peyer
patch
pp
infect
individu
product
mucu
fae
also
reduc
facilit
uptak
pathogen
cell
process
underli
mucos
immun
system
overal
great
divers
rotaviru
strain
limit
number
genotyp
play
domin
role
larg
defin
makeup
rotaviru
vaccin
date
host
genet
also
impact
viral
entri
vaccin
develop
could
benefit
genotyp
screen
region
nation
popul
similarli
case
influenza
regular
monitor
preval
viral
strain
could
lead
better
adjust
vaccin
patient
need
although
case
rotaviru
aspect
clearli
establish
final
take
account
capac
cell
uptak
antigen
optim
deliveri
could
increas
vaccin
effici
see
take
account
mortal
morbid
caus
rotaviru
infect
sever
vaccin
develop
year
live
attenu
variant
natur
occur
strain
vaccin
tradit
obtain
multipl
round
passag
cell
cultur
pioneer
bovin
demonstr
overal
efficaci
phase
iii
clinic
trial
never
commerci
latergener
vaccin
includ
rhesu
monkeyhuman
tetraval
reassort
rrvtv
later
licens
rotashield
soon
remov
market
due
increas
risk
intussuscept
rare
pain
potenti
lifethreaten
bowel
obstruct
event
human
monoval
commerci
rotarix
gsk
dose
week
pentaval
bovinehuman
reassort
market
merck
rotateq
dose
week
earli
studi
point
discrep
vaccin
efficaci
compar
result
low
high
child
mortal
set
overal
metaanalysi
rotarix
rotateq
perform
trial
respect
involv
particip
low
high
child
mortal
set
indic
low
mortal
region
rotarix
prevent
sever
rge
case
infant
year
age
respect
rotateq
prevent
sever
rge
case
infant
year
age
respect
high
child
mortal
region
rotarix
prevent
sever
rge
case
infant
year
age
respect
rotateq
prevent
sever
rge
case
infant
year
age
respect
vaccin
regard
safe
signific
differ
advers
event
note
vaccin
placebo
group
intussuscept
case
children
rotarix
children
follow
rotateq
anoth
exampl
lanzhou
lamb
rotaviru
vaccin
llr
genotyp
licens
china
sinc
one
doseyear
year
children
month
old
base
studi
compris
children
immun
least
one
dose
overal
protect
rate
found
total
popul
year
old
attenu
strain
develop
licens
vietnam
regard
safe
compar
seroconvers
rotarix
clinic
trial
vaccin
undergo
develop
clinic
trial
licensur
includ
natur
occur
reassort
monoval
humanbovin
rotaviru
vaccin
rotavac
bharat
biotech
intern
strain
phase
iii
clinic
trial
vaccin
administ
week
age
vaccin
placebo
base
observ
year
age
efficaci
sever
rge
intussuscept
case
vaccin
placebo
group
respect
p
anoth
vaccin
evalu
pentaval
bovinehuman
reassort
vaccin
develop
serum
institut
india
brvpv
compris
serotyp
clinic
trial
take
place
niger
use
dose
regimen
week
age
cohort
infant
vaccin
placebo
group
respect
author
report
efficaci
sever
rge
case
intussuscept
import
note
vaccin
efficaci
may
also
vari
cours
year
premkumar
et
al
evalu
efficaci
rotarix
rotateq
america
depend
level
exposur
rotaviru
season
defin
presenc
rotaviru
stool
sampl
case
juli
decemb
bolivia
februari
june
el
salvador
februari
may
guatemala
januari
april
nicaragua
usa
base
cohort
particip
age
month
complet
full
cours
vaccin
case
control
infant
month
age
vaccin
efficaci
lower
born
rotaviru
season
vs
children
month
overal
signific
differ
vs
outsid
rotaviru
season
respect
brief
current
two
liveattenu
rotaviru
vaccin
global
distribut
show
higher
efficaci
develop
nation
china
india
vietnam
also
vaccin
licens
local
sever
evalu
clinic
trial
worldwid
includ
nonrepl
vaccin
research
thermost
formul
address
need
develop
nation
often
lack
requir
cold
chain
capac
storag
distribut
vaccin
america
vaccin
efficaci
appear
decreas
rotaviru
season
observ
translat
rest
world
adjust
dose
could
potenti
improv
outcom
immun
live
attenu
vaccin
without
risk
illustr
rotashield
mitig
advers
event
improv
dose
regimen
safer
strain
therefor
import
consider
see
aftermath
voluntari
withdraw
rotashield
market
due
increas
risk
intussuscept
safeti
benefit
rotaviru
vaccin
subject
substanti
scrutini
comment
usabas
report
evalu
occurr
intussuscept
state
infant
age
month
note
develop
condit
also
vaccin
rotashield
incid
greater
day
vaccin
especi
first
dose
account
second
third
estim
increas
case
intussuscept
vaccin
program
fulli
implement
infant
vaccin
overal
studi
show
strong
tempor
specif
associ
vaccin
administr
intussuscept
conclud
vaccin
better
safeti
profil
requir
anoth
studi
evalu
impact
age
incid
intussuscept
rotashield
administr
note
infant
day
old
first
dose
repres
case
despit
receiv
sole
first
dose
overal
vaccin
schedul
could
complet
day
age
dose
reduc
intussuscept
incid
strategi
test
rrvtv
ghana
despit
withdrawn
european
usa
market
base
data
infant
vaccin
placebo
group
efficaci
rge
sever
serotyp
present
vaccin
serotyp
case
intussuscept
report
postlicens
evalu
intussuscept
risk
usa
compris
dose
rotateq
first
dose
dose
rotarix
first
dose
author
perform
two
analys
rotateq
primari
analysi
indic
associ
vaccin
intussuscept
highest
day
first
dose
excess
infant
receiv
first
dose
risk
window
excess
case
infant
receiv
first
dose
risk
window
secondari
analysi
identifi
attribut
risk
excess
infant
receiv
first
dose
risk
window
risk
attribut
dose
limit
number
rotarix
dose
allow
precis
estim
intussuscept
risk
therefor
prevent
direct
comparison
rotateq
secondari
analysi
indic
signific
attribut
risk
second
dose
excess
infant
risk
window
import
continu
monitor
risk
associ
rotaviru
vaccin
low
incom
nation
data
high
incom
set
may
directli
compar
iron
although
efficaci
rotaviru
vaccin
lower
develop
nation
also
region
benefit
greater
magnitud
due
higher
burden
diseas
take
consider
diseas
burden
associ
cost
hospit
well
mortal
rotaviru
gastroenter
impact
vaccin
predict
signific
estim
gavielig
countri
vaccin
could
prevent
million
child
death
million
disabilityadjust
life
year
accord
troeger
et
al
decreas
mortal
among
children
year
age
probabl
due
part
vaccin
introduct
possibl
mass
introduct
vaccin
could
lead
emerg
escap
mutant
regard
et
al
look
preval
rotaviru
strain
cours
year
introduct
rotarix
rotateq
strain
frequenc
similar
vaccin
campaign
domin
one
numer
countri
report
increas
frequenc
strain
emerg
ie
evid
global
emerg
new
one
howev
studi
brazil
nicaragua
suggest
genet
reassort
vaccin
wildtyp
wt
strain
rotarix
rotateq
respect
probabl
influenc
vaccin
efficaci
also
higher
frequenc
heterotyp
countri
rotarix
use
also
observ
rotateqadopt
countri
within
region
gener
natur
strain
variat
year
could
mistaken
genet
drift
caus
introduct
vaccin
monitor
requir
assess
strain
evolut
especi
lead
lower
vaccin
efficaci
overal
rotaviru
vaccin
clearli
outweigh
risk
advers
event
intussuscept
across
geographi
demograph
simpl
strategi
includ
avoid
immun
age
peak
natur
occurr
significantli
reduc
intussuscept
incid
compel
evid
select
pressur
natur
occur
strain
due
mass
introduct
rotaviru
vaccin
continu
monitor
advis
addit
area
intervent
discuss
eg
sanit
environment
enteropathi
nutrit
statu
matern
antibodi
sever
establish
emerg
area
could
allow
improv
efficaci
oral
rotaviru
vaccin
develop
nation
includ
optim
deliveri
mucos
adjuv
find
action
target
system
vaccinolog
approach
chronobiolog
mucos
vaccin
deliveri
mucos
surfac
human
adult
compris
higher
skin
area
therefor
present
ampl
opportun
pathogen
entri
infect
take
place
via
rout
also
immun
ideal
mucos
vaccin
lead
appropri
adapt
respons
without
excess
inflamm
tissu
damag
side
effect
aris
stimul
wrong
target
cell
mucos
epitheli
cell
eg
product
proinflammatori
cytokin
antigen
uptak
present
intestin
lung
mucos
tissu
reli
dendrit
cell
dc
cell
latter
compris
basolater
pocket
facilit
transcytosi
antigen
virus
bacteria
contact
underli
lymphoid
tissu
antigen
deliv
follicular
b
cell
mucos
dc
present
cargo
cell
transit
mesenter
lymph
node
fact
cell
spars
million
intestin
epitheli
cell
may
reflect
mechan
selfprotect
food
allergi
inflammatori
diseas
mice
studi
show
cell
differenti
highli
regul
process
although
increas
cell
number
achiev
modul
prolifer
eg
rankl
target
cell
specif
ligand
may
safer
approach
ideal
cell
marker
would
membranebound
favour
intern
tag
cargo
also
conserv
among
differ
human
preclin
anim
model
enabl
effici
translat
result
howev
find
univers
cell
marker
proven
difficult
research
field
includ
work
lewi
antigen
sever
group
search
cellspecif
target
ligand
kim
et
al
screen
human
cell
model
cocultur
phage
display
peptid
librari
one
peptid
sfhqlparsplp
facilit
transcytosi
fusion
cell
mous
intestin
also
led
higher
antigfp
serum
igg
faecal
iga
upon
oral
immun
similar
data
report
fusion
dengu
viru
envelop
domain
ediii
protein
also
mice
oral
immun
gpfomph
peptid
fusion
akiaivnvsrifqqlpeset
led
higher
igg
faecal
iga
respons
toward
gfp
compar
gfp
alon
fusion
mucos
vaccin
becom
dilut
fluid
miss
target
due
bulk
flow
degrad
proteas
critic
appropri
design
retain
ideal
biophys
properti
hydrophil
uncharg
surfac
favour
mucu
penetr
adhes
mucu
promot
hydrophobicityposit
charg
eg
chitosan
cellulos
deriv
polyethyleneglycol
also
favor
adhes
mucu
diffus
kda
kda
respect
anoth
exampl
peptid
found
phage
display
mediat
cell
entri
cksthplsc
conjug
swine
dysenteri
bacteri
antigen
bmpb
load
poli
lacticcoglycol
acid
plga
particl
coat
watersolubl
chitosan
oral
immun
mice
particl
led
increas
faecal
siga
igg
respons
importantli
plga
frequent
use
drug
deliveri
system
regard
safe
singh
et
al
describ
ileumtarget
protein
deliveri
system
base
commonli
use
safe
hydroxypropyl
methylcellulos
phthalat
thiolat
form
thpmcp
deliveri
favour
mucoadhes
slower
releas
payload
upon
oral
immun
mice
mbmpb
antigen
encapsul
particl
harbour
higher
iga
igg
content
faec
serum
respect
compar
mbmpb
alon
human
cell
frequent
studi
cocultur
raji
cell
line
recent
work
show
human
intestin
crypt
grown
monolay
differenti
cell
upon
addit
rankl
lead
increas
microparticl
uptak
latter
novel
system
could
interest
identifi
new
marker
improv
current
understand
cell
biolog
enzymat
degrad
clearanc
via
mucu
secret
bulk
movement
limit
effici
oral
vaccin
deliveri
extent
form
transgen
plantexpress
antigen
protect
gut
digest
without
induc
toler
properli
dose
instanc
transgen
rice
express
cholera
toxin
b
mucoricectb
shown
potenti
express
longtim
storag
vaccin
antigen
seed
within
storag
organel
protein
bodi
remain
protect
digest
therefor
retain
immunogen
ingest
rice
powder
mgcours
ctb
total
dose
everi
weeksmous
uptak
via
cell
induc
igg
serum
siga
faec
oral
administr
similar
amount
recombin
purifi
ctb
bare
elicit
iga
incid
diarrhoea
latter
none
former
mucoricectb
also
provid
crossprotect
enterotoxigen
e
coli
lower
level
igg
faecal
siga
toward
ctb
technolog
current
evalu
clinic
trial
oral
immun
region
affect
environment
enteropathi
lead
lower
vaccin
efficaci
altern
form
administr
microneedl
transderm
patch
could
therefor
interest
bypass
constraint
target
dens
network
antigenpres
cell
apc
dermi
epidermi
compar
skelet
muscl
provid
overal
similar
increas
immunogen
intramuscular
deliveri
show
high
stabil
dosespar
capabl
microneedl
gener
regard
safe
clinic
trail
simpli
painlessli
appli
singl
dose
without
requir
special
train
vaccin
reconstitut
sharp
wast
take
account
massproduc
less
us
per
unit
microneedl
patch
could
econom
appeal
low
incom
area
solid
metal
silicon
polymer
coat
dri
vaccin
selfdissolv
eg
vaccin
encapsul
watersolubl
materi
releas
antigen
adjuv
skin
vaccin
made
avail
dri
formul
may
compris
stabil
adjuv
thu
reduc
cold
chain
need
appli
preclin
clinic
studi
varieti
pathogen
sourc
live
attenu
virus
inactiv
virus
viral
subunit
vlp
bacteri
antigen
also
dna
vaccin
instanc
moon
et
al
compar
singl
dose
stainless
steel
microneedl
patch
intramuscular
inject
deliveri
unadjuv
human
inactiv
rotaviru
vaccin
mice
found
igg
level
induc
dose
deliv
microneedl
least
effici
dose
given
via
intramuscular
rout
day
inject
also
spleen
analysi
indic
deliveri
method
seem
equal
effici
induc
recal
respons
anoth
studi
test
hollow
microneedl
inject
devic
deliv
three
dose
vaccin
without
adjuv
compar
equal
intramuscular
im
inject
adjuv
aluminium
hydroxid
piglet
day
follow
challeng
human
wa
rotaviru
day
author
found
sign
reactogen
site
inject
day
iga
igg
serum
mean
titr
higher
im
administr
compar
microneedl
signific
differ
day
still
higher
im
evalu
viral
shed
diarrhoea
challeng
indic
stronger
protect
piglet
immun
microneedl
im
anoth
approach
overcom
barrier
ee
pose
classic
oral
vaccin
deliveri
sublingu
administr
advantag
dermal
vaccin
includ
absenc
keratin
surfac
cell
prevent
simpler
access
apc
buccal
sublingu
rout
lead
antigen
uptak
min
differ
saliva
composit
ph
flow
rate
potenti
obstacl
buccal
vaccin
deliveri
exampl
includ
live
attenu
virus
inactiv
vaccin
influenza
adenovir
vector
deliv
antigen
preclin
model
eg
influenza
ha
hiv
ebola
bacteri
vaccin
b
subtilisexpress
toxin
inactiv
vaccin
includ
nonrepl
formul
requir
adjuv
cpg
detoxifi
ct
lt
proper
mucos
respons
eg
hpv
rsv
hiv
compon
protein
work
preclin
assay
intranas
vaccin
also
show
promis
provid
vector
adjuv
properli
sourc
technolog
current
approv
live
attenu
influenza
vaccin
therefor
possibl
rout
administr
could
use
circumv
limit
oral
rotaviru
immun
interestingli
simian
porcin
rotaviru
shown
adjuv
properti
mice
coadminist
model
antigen
increas
serum
igg
faecal
iga
respons
addit
intranas
intramuscular
deliveri
recombin
human
rotaviru
combin
noroviru
viruslik
particl
led
reduct
least
rotaviru
shed
faec
upon
rotaviru
challeng
mice
live
cultur
lactic
acid
bacteria
also
use
mucos
vaccin
deliveri
quit
resist
gastric
acid
encapsul
protect
surfacedisplay
antigen
advers
condit
also
differ
strain
distinct
adjuv
adhes
abil
persist
gut
vari
amount
time
lead
express
divers
cytokin
exampl
includ
oral
intranas
deliveri
sar
coronaviru
spike
protein
display
lactobacillu
casei
mice
lead
specif
serum
igg
well
intestin
lung
iga
respons
vitro
neutral
activ
also
lactococcu
lacti
express
antigen
without
coadministr
strain
express
use
intranas
immun
mice
follow
lethal
challeng
tumour
cell
line
mice
treat
tumourfre
day
remain
mice
significantli
smaller
tumour
size
cm
control
immun
l
lacti
alon
perish
day
median
tumour
cm
summari
cell
target
receiv
consider
attent
increas
mucos
vaccin
effici
although
low
number
rais
risk
advers
reaction
led
sever
group
discov
natur
occur
randomli
select
cellspecif
target
peptid
tether
antigen
moieti
lead
higher
immun
respons
mucosa
serum
addit
encapsul
antigen
nanoparticl
allow
protect
cargo
digest
tract
enzym
mucoadhes
phdepend
releas
differ
locat
gut
cellenrich
ileum
altern
immun
method
compris
eg
transgen
plant
may
allow
vaccin
antigen
express
deliveri
also
long
term
storag
also
intraderm
buccalsublingu
intranas
deliveri
could
offer
solut
overcom
barrier
ee
oral
administr
vaccin
challeng
part
due
hyporespons
toler
issu
adjuv
act
enhanc
modul
immun
respons
therefor
allow
lower
less
frequent
dose
antigen
save
prove
critic
import
case
pandem
also
hold
promis
enhanc
respons
children
immunosenesc
immunocompromis
patient
adjuv
stimul
innat
immun
system
act
dc
macrophag
neutrophil
also
adapt
immun
system
discuss
encapsul
biodegrad
particul
deliveri
system
mucos
adjuv
promis
approach
protect
digest
enzym
live
attenu
vaccin
harbour
multipl
antigen
also
serv
adjuv
inactiv
vaccin
gener
lower
efficaci
compon
may
lack
ideal
function
subunit
vaccin
also
show
poor
immunogen
therefor
need
adjuv
elicit
satisfactori
respons
instanc
encourag
result
report
preclin
studi
graft
epitop
onto
appropri
scaffold
eg
immun
structur
similar
region
differ
pathogen
eg
candida
albican
adhesin
confer
protect
staphylococcu
aureu
via
adhesin
clfa
similar
observ
made
target
substitut
within
n
meningitidi
fhbp
compon
bexesero
vaccin
result
emphas
need
discoveri
suitabl
mucos
adjuv
bacteri
toxin
induc
strong
local
system
immun
respons
exampl
reach
commerci
inactiv
intranas
virosomalsubunit
influenza
vaccin
supplement
e
coli
adpribosyl
heatlabil
toxin
lt
mucos
adjuv
although
prelicensur
trial
includ
individu
winter
show
seriou
side
effect
follow
introduct
vaccin
case
bell
palsi
record
cours
month
repres
estim
rel
risk
increas
lead
vaccin
withdrawn
market
although
lt
also
cholera
toxin
detoxifi
use
limit
anim
model
clinic
trial
detoxifi
version
bacteri
toxin
normal
less
potent
adjuv
origin
molecul
phase
clinic
trial
intranas
influenza
vaccin
compris
mutant
detoxifi
form
lt
toxin
well
toler
adjuv
dose
within
cohort
volunt
howev
phase
clinic
trial
intranas
hiv
tuberculosi
vaccin
adjuv
dose
two
healthi
volunt
show
symptom
transient
bell
palsi
data
indic
nasal
deliveri
toxin
advis
regard
lt
doubl
mutant
dmlt
use
adjuv
clinic
trial
oral
enterotoxigen
e
coli
vaccin
shown
well
toler
effect
increas
immun
respons
among
cohort
swedish
volunt
certain
cytokin
also
show
potenti
mucos
adjuv
cholera
toxin
ct
increas
level
mucos
epitheli
cell
therefor
test
adjuv
intranas
immun
mice
ovalbumin
tetanu
toxoid
shown
increas
igg
iga
vagin
lavag
manner
compar
superior
ct
similarli
kayamuro
et
al
test
interleukin
adjuv
intranas
immun
mice
influenza
ha
note
famili
member
effect
increas
igg
iga
level
serum
saliva
nasal
wash
faecal
extract
vagin
wash
respect
author
also
found
upon
viral
challeng
mice
immun
ha
cytokin
adjuv
aliv
day
within
time
frame
receiv
ha
perish
none
mock
vaccin
pb
aliv
also
sign
sever
inflamm
tissu
damag
nasal
caviti
interest
note
evid
role
glutamin
favour
intestin
iga
product
sever
studi
describ
induct
mucos
immun
parenter
administr
adjuv
hein
et
al
use
e
coli
doubl
mutant
lt
dmlt
improv
immun
respons
shigella
antigen
ipab
ipad
deliv
intraderm
use
microneedl
mice
immun
time
week
interv
lead
quick
infiltr
neutrophil
macrophag
dendrit
langerhan
cell
well
cell
igg
level
serum
elev
contrari
observ
made
control
intranas
immun
iga
detect
serum
stool
intranas
deliveri
also
led
antibodi
igg
iga
secret
cell
lung
spleen
bone
marrow
intraderm
inject
led
igg
secret
spleen
bone
marrow
interestingli
intraderm
vaccin
provid
protect
lethal
pulmonari
challeng
flexneri
sonnei
respect
without
dmlt
adjuv
intranas
vaccin
deliveri
provid
protect
antigenspecif
igg
present
lung
mucos
fluid
intraderm
immun
igg
iga
detect
intranas
deliveri
frederick
et
al
compar
effect
cpg
dmlt
combin
mhc
class
ii
cell
peptid
antigen
intramuscular
intraderm
ear
immun
mice
dmlt
superior
cpg
expand
maintain
antigenspecif
cell
lymph
node
spleen
induc
intestin
home
integrin
spleen
mesenter
lymph
node
small
larg
intestin
lamina
propria
also
greater
number
antigenspecif
cell
intramuscular
intraderm
immun
flank
gave
similar
result
indic
adjuv
rout
administr
determin
cell
migrat
intestin
tissu
cpg
lead
cell
bia
dmlt
result
respons
brief
adjuv
play
major
role
stimul
immun
respons
especi
inactiv
subunit
vaccin
although
sever
proven
singl
compon
combin
adjuv
avail
parenter
immun
mucos
adjuv
harder
develop
follow
toxic
problem
clinic
e
coli
lt
detoxifi
version
lt
ct
well
cytokin
explor
clinic
trial
intraderm
immun
adjuv
dmlt
seem
trigger
igg
antigenspecif
cell
intestin
iga
latter
present
intranas
deliveri
serum
stool
sampl
genet
makeup
environ
age
gender
microbiom
bodymass
index
exert
great
influenc
outcom
immun
better
understand
divers
individu
respons
vaccin
therefor
predict
outcom
sever
group
pursu
genet
system
biologyvaccinolog
approach
look
essenti
outcom
parenter
immun
studi
integr
inform
gather
genom
variat
gene
express
cytokin
chemokin
analysi
multiparamet
flow
cytometri
metabolom
comput
model
instanc
studi
gambia
monozyg
dizyg
infant
twin
pair
live
togeth
look
environment
vs
genet
regul
immun
respons
bcg
oral
polio
hepb
diphtheria
pertussi
tetanu
month
antibodi
respons
herit
particularli
case
hepb
polio
vaccin
genet
factor
special
nonhla
gene
play
import
role
modul
vaccin
respons
infant
anoth
twin
studi
analys
monozyg
dizyg
healthi
pair
year
old
differ
immun
paramet
compris
cell
popul
frequenc
cytokin
respons
serum
protein
innat
adapt
cell
popul
frequenc
influenc
mostli
nonherit
paramet
popul
other
strong
influenc
herit
factor
articl
also
report
serum
protein
measur
show
great
variat
herit
addit
author
look
variat
herit
trait
young
older
mz
twin
cohort
median
median
year
old
respect
note
sever
case
decreas
correl
age
like
reflect
differ
environment
exposur
possibl
also
epigenet
chang
analysi
antibodi
respons
season
influenza
vaccin
indic
influenc
mostli
nonherit
compon
overal
herit
immun
trait
tend
decreas
age
like
reflect
effect
exposur
environ
studi
indic
genet
influenc
immun
respons
associ
code
noncod
region
genom
strong
influenc
environment
factor
querec
et
al
also
use
system
vaccinolog
method
identifi
marker
predict
respons
yellow
fever
vaccin
evalu
healthi
volunt
st
year
nd
year
day
note
gene
modul
trial
associ
immunolog
respons
cell
motil
peak
gene
express
observ
day
largest
categori
involv
antivir
interferon
respons
interestingli
transcript
level
day
predict
antibodi
respons
trial
anoth
exampl
system
vaccinolog
came
analysi
signatur
live
attenu
laiv
n
trival
inactiv
influenza
vaccin
tiv
n
data
show
poor
respons
laiv
day
induc
plasma
sampl
tiv
microarray
data
pbmc
individu
day
show
gene
differenti
modul
vaccin
includ
common
inflammatori
antimicrobi
gene
tiv
laiv
also
interferon
gene
modul
laiv
like
due
viru
replic
overal
distinct
signatur
laiv
tiv
latter
vaccin
also
show
upregul
antibodi
respons
predict
kinas
camkiv
involv
cell
develop
inflammatori
respons
mainten
hematopoiet
stem
cell
day
paramet
neg
correl
antibodi
respons
day
immun
ko
camkiv
control
wt
mice
tiv
led
higher
respons
day
ko
similar
system
vaccinolog
analys
publish
tsang
et
al
influenza
vaccin
li
et
al
meningococcu
vaccin
nakaya
et
al
sobolev
et
al
also
use
multifactori
analysi
studi
impact
adjuv
influenza
vaccin
metabolom
also
recent
employ
overal
despit
grow
interest
system
vaccinolog
lack
common
genet
marker
predict
immun
respons
vaccin
type
determin
broad
transcript
output
eg
bacteri
polysaccharid
vs
inactiv
viral
vaccin
also
adjuv
mitig
variat
respons
magnitud
associ
children
elderli
subject
addit
need
integr
omic
studi
fill
current
gap
understand
mucos
adjuv
especi
young
children
theori
ration
modul
posit
neg
regul
vaccin
respons
could
potenti
improv
efficaci
vaccin
campaign
estim
genom
circadian
control
regul
light
pattern
food
intak
anoth
power
cue
circadian
clock
import
gatekeep
reduc
immunityassoci
cost
increas
overal
fit
mediat
extern
cue
intern
oscil
immun
cell
nearli
branch
innat
adapt
immun
respons
show
circadian
oscil
clock
activ
transcript
bind
ebox
per
cri
reverb
delay
enter
nucleu
repress
clock
activ
transcript
activ
transcript
compet
bind
site
repressor
third
loop
includ
transcript
activ
dbp
repressor
regul
express
dboxcontrol
gene
per
ultim
transcript
oscil
key
regul
lead
circadian
cue
cellular
process
cycl
peripher
clock
orchestr
central
clock
use
essenti
compon
virtual
cell
diseas
show
circadian
time
eg
ra
symptom
exacerb
earli
morn
correl
high
tnf
serum
level
address
matter
chronopharmacolog
aim
optim
drug
administr
peak
efficaci
minim
side
effect
gain
better
understand
circadian
regul
global
gene
express
zhang
et
al
use
transcriptom
organ
mice
adren
gland
aorta
brainstem
brown
fat
cerebellum
heart
hypothalamu
kidney
liver
lung
skelet
muscl
white
fat
analys
circadian
gene
express
microarray
rnaseq
found
proteincod
gene
oscil
least
one
organ
transcript
oscil
includ
core
clock
gene
author
also
note
rush
hour
transcript
circadian
gene
time
preced
dawn
dusk
circadian
gene
cluster
physic
within
genom
importantli
mani
gene
product
physic
modul
drug
show
circadian
pattern
essenti
medicin
modul
circadian
gene
includ
us
top
sell
drug
nearli
half
halfliv
find
emphas
import
dose
appropri
time
decreas
side
effect
minimum
circadian
regul
gene
express
also
note
mice
intestin
includ
patternrecognit
receptor
circadian
rhythm
influenc
critic
compon
innat
adapt
immun
exampl
patternrecognit
receptor
bacteri
viral
dna
cpg
follow
mice
vaccin
ovalbumin
adjuv
cpg
time
higher
express
adapt
respons
stronger
also
diseas
sever
sepsi
mous
model
correl
level
circadian
rhythm
also
affect
viral
replic
instanc
edgar
et
al
address
effect
circadian
rhythm
herp
influenza
viru
use
murin
strain
infect
wt
ko
mice
cell
line
wt
mice
infect
recombin
murid
herpesviru
onset
rest
phase
greater
replic
infect
activ
phase
contrast
ko
show
high
level
viral
replic
time
similar
data
obtain
use
herp
simplex
viru
indic
effect
strainspecif
circadian
rhythm
could
therefor
modul
respons
vaccin
regardless
rout
immun
sleep
depriv
known
disrupt
circadian
rhythm
correl
lower
vaccin
respons
hepat
hepat
b
howev
karabay
et
al
notic
differ
hepat
b
respons
volunt
vaccin
morn
afternoon
also
long
et
al
analys
impact
time
day
vs
pm
influenza
vaccin
efficaci
cohort
year
old
uk
citizen
show
immun
disord
infect
morn
afternoon
vaccin
evalu
antibodi
titr
cytokin
steroid
hormon
level
serum
took
place
month
vaccin
strain
show
higher
respons
morn
vaccin
b
strain
hai
assay
influenc
cytokin
steroid
level
anoth
report
analys
impact
sampl
collect
immun
time
elderli
n
year
old
younger
individu
n
age
within
blood
sampl
collect
day
day
vaccin
evid
effect
time
immun
data
indic
signific
increas
igg
igm
titr
day
older
group
younger
sampl
collect
afternoon
suggest
time
sampl
collect
affect
interpret
vaccin
outcom
brief
circadian
rhythm
play
critic
role
modul
express
genom
includ
gene
associ
therapeut
intervent
innat
adapt
immun
system
except
intestin
tissu
also
regul
evid
also
suggest
circadian
rhythm
play
role
viru
life
cycl
therefor
time
immun
could
potenti
import
studi
requir
especi
field
mucos
vaccin
differ
rotaviru
vaccin
efficaci
note
high
lowincom
countri
indic
novel
appropri
effect
vaccin
develop
address
specif
requir
popul
need
current
knowledg
gap
mucos
immun
respons
rotaviru
infect
increas
understand
area
especi
among
young
children
would
like
provid
critic
insight
also
littl
inform
role
circadian
rhythm
vaccin
respons
studi
special
address
mucos
immun
need
howev
known
preclin
model
viru
infect
affect
also
instanc
express
critic
patternrecognit
receptor
associ
respons
pathogen
tlr
includ
intestin
tissu
depend
circadian
rhythm
order
address
current
gap
knowledg
perform
integr
system
vaccinolog
omic
analysi
intestin
mucos
immun
healthi
human
variou
age
ethnicgenet
background
rotaviru
vaccin
could
prove
inform
would
compris
also
evalu
circadian
pattern
express
includ
gene
associ
pathogen
entri
studi
could
extend
individu
affect
differ
level
entheropathi
match
ageethn
genet
background
analys
output
could
provid
new
venu
intervent
compens
defect
critic
pathway
relat
eg
pathogen
entri
immun
respons
affect
sick
individu
simpl
solut
use
pertin
adjuv
well
time
provis
supplement
possibl
also
sourc
local
avail
food
remedi
addit
circadian
gene
express
pattern
would
potenti
give
indic
whether
vaccin
administr
specif
time
day
could
contribut
higher
efficaci
grow
evid
suggest
studi
requir
valid
identifi
critic
rotaviru
entri
factor
individu
differ
genet
background
explor
potenti
improv
emerg
cell
cultur
system
better
mimic
gut
tissu
could
prove
use
would
assist
identifi
evalu
specif
rotaviru
entri
factor
cell
cultur
repres
genet
divers
individu
specif
entri
factor
could
potenti
use
marker
easili
probe
children
genet
background
low
cost
kit
preliminari
stage
mass
vaccin
campaign
follow
tailor
vaccin
would
administ
individu
furthermor
could
import
design
decoy
base
pathogen
entri
factor
tailor
children
genet
background
preval
strain
given
area
instanc
strain
recogn
host
lactonbios
nacetyllactosamin
affect
indian
newborn
block
receptor
suitabl
decoy
would
like
antagon
entri
strain
henc
tailor
medic
could
administ
genotyp
children
day
vaccin
therefor
reduc
incid
gastroenter
prior
vaccin
increas
effici
immun
favour
entri
vaccin
rather
pathogen
strain
would
necessari
evalu
ideal
dosinghalflif
decoy
well
consid
whether
vaccin
administ
high
low
rotaviru
season
ascertain
genet
makeup
local
popul
regard
rotaviru
entri
factor
would
equal
import
monitor
strain
natur
occur
given
region
case
annual
influenza
immun
campaign
domin
strain
would
continu
guid
design
new
vaccin
deploy
would
adjust
geograph
area
patient
question
improv
vaccin
target
cell
exist
novel
ligand
includ
small
molecul
use
better
cell
cultur
system
vaccin
encapsul
strategi
would
like
rais
immun
effici
develop
nation
regard
old
potenti
new
ligand
could
valid
vitro
use
translat
fusion
conjug
pertin
deliveri
system
lactic
acid
bacteria
subunit
vaccin
synthet
nanoparticl
rotaviru
spike
head
protein
find
would
extend
vivo
assay
use
appropri
preclin
model
promis
lead
evalu
clinic
trial
base
outcom
omic
analysi
regard
mucos
immun
may
possibl
hypothes
candid
mucos
adjuv
could
lead
increas
antigenspecif
cell
base
immun
also
iga
secret
gut
could
potenti
administ
via
intraderm
rout
use
eg
microneedl
therefor
bypass
constraint
associ
enteropathi
requir
cold
chain
altern
potenti
lowcost
strategi
vaccin
product
storag
transgen
plant
seem
gain
traction
exemplifi
oral
deliveri
rice
express
cholera
toxin
principl
approach
could
also
explor
rotaviru
vaccin
futur
expect
signific
develop
number
field
like
shape
rotaviru
vaccin
develop
new
data
regard
critic
rotaviru
entri
factor
distribut
across
popul
especi
low
incom
area
current
vaccin
underperform
probabl
emerg
valid
technolog
compris
polym
encapsul
cell
target
vaccin
expect
like
benefit
improv
cell
cultur
method
system
analysi
rotaviru
vaccin
infect
mucos
patholog
immun
help
clarifi
import
question
regard
intervent
mitig
ee
test
valid
suitabl
mucos
adjuv
key
pathway
involv
well
circadian
regul
rotaviru
entri
factor
respons
vaccin
progress
also
expect
altern
deliveri
method
formul
thermost
vaccin
overal
forese
advanc
field
translat
promis
new
gener
vaccin
could
enter
clinic
trial
come
year
rotaviru
gastroenter
lead
caus
diarrheal
death
estim
annual
toll
children
diseas
occurr
modul
access
clean
water
sanit
climat
poverti
nutrit
contribut
environment
enteropathi
current
vaccin
wide
deploy
regard
safe
show
inferior
efficaci
low
incom
nation
incid
diseas
highest
effici
vaccin
requir
address
need
poorer
countri
research
area
mucos
immun
adjuv
system
vaccinolog
deliveri
stabil
like
shape
next
gener
rotaviru
vaccin
potenti
conflict
interest
report
author
dg
employe
msd
wellcom
trust
hilleman
lab
pvt
ltd
fund
research
